title: Apheresis-elutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients.
abstract: Human blood monocytes (Mo) and monocyte-derived macrophages (M phi) are known to be potent antitumor cytotoxic effector cells through activation with recombinant human interferon gamma (rIFN-gamma), bacterial muramyldipeptide or the synthetic derivative muramyltripeptide phosphatidylethanolamine entrapped in liposomes (L-MTP-PE). Large-scale generation of ex vivo activated Mo from the blood of cancer patients proved feasible. We report our experience with a fixed rotor speed counterflow centrifugation elutration (CEE) procedure using the newly available Beckman high capacity JE-5.0 rotor system that reproducibly isolates up to 1.0-1.5 x 10(9) Mo with greater than 90% purity, in suspension and functionally intact derived from peripheral blood mononuclear cell-enriched suspensions obtained by leukapheresis (LP) from healthy volunteers and cancer patients. The semiclosed, easy to handle CCE system, was adapted to a sterile technique that permitted clinical trials in adoptive monocyte immunotherapy. Freshly isolated Mo did not lose morphological or functional integrity and had no spontaneous activation. Their abilities to become activated to the cytotoxic state after 18-h stimulation with 500 U/ml rIFN-gamma or 1 microgram/ml L-MTP-PE and to differentiate into matured M phi in vitro were not altered. The system was therefore used to isolate large numbers of Mo for a phase I clinical trial of intraperitoneal immunotherapy with L-MTP-PE activated autologous Mo in nine patients with peritoneal carcinomatosis. Each patient received weekly Mo infusions (n = 5) with an intrapatient dose escalation schedule (from 10(7) to 10(9) Mo). Toxicities were mild including fever, chills and abdominal pain. There was no treatment-induced thromboembolic event or capillary leak syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département d'Onco-Hématologie, CHU Hautepierre, Strasbourg, France.
authors.forename: A
authors.initials: A
authors.lastname: Faradji
authors.forename: A
authors.initials: A
authors.lastname: Bohbot
authors.forename: M
authors.initials: M
authors.lastname: Schmitt-Goguel
authors.forename: S
authors.initials: S
authors.lastname: Dumont
authors.forename: A
authors.initials: A
authors.lastname: Eischen
authors.forename: M L
authors.initials: ML
authors.lastname: Wiesel
authors.forename: A
authors.initials: A
authors.lastname: Stierle
authors.forename: G
authors.initials: G
authors.lastname: Follea
authors.forename: M
authors.initials: M
authors.lastname: Eber
authors.forename: J P
authors.initials: JP
authors.lastname: Bergerat
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives; D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000818:Animals; D001781:Blood Component Removal; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000295:instrumentation / Q000379:methods*; D008081:Liposomes; D051379:Mice; D008875:Middle Aged; D016260:Monocytes, Activated Killer; D010534:Peritoneal Neoplasms / Q000628:therapy*; D010714:Phosphatidylethanolamines
chemical_list: D000276:Adjuvants, Immunologic; D008081:Liposomes; D010714:Phosphatidylethanolamines; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine